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SHORT COMMUNICATION
Psoriasis is a common, and currently incurable chronic 
immune-mediated skin disease (1), with incompletely 
understood etiology partially due to the unavailability 
of animal models that can emulate major features of 
the disease. The phospho-inositol-3 kinase (PI3K)/pro-
tein kinase B(Akt) and mammalian target of rapamycin 
(mTOR) signaling which regulate metabolism, cell proli-
feration, survival, apoptosis, and frequently deregulated 
in diverse cancers (2, 3), has recently emerged as a clini-
cally relevant target for inflammatory diseases including 
psoriasis (4, 5). This pathway is tightly regulated through 
feedback loops in part via 2 mTOR complexes, (C1 and 
2), with linkage through Akt. PI3K activation triggers 
the phosphorylation of a 3-hydroxyl group, which then 
activates Akt kinase and promotes keratinocyte hyper-
proliferation and inhibit differentiation, as observed in 
psoriasis (4). Initial clinical data suggest that second-
generation inhibitors (targeting both mTOR and PI3-K 
kinases) provide therapeutic benefit for psoriasis (6). 
Additionally, psoriasis-associated epidermal-type fatty 
acid-binding protein (FABP-5) involved in cytosolic fatty 
acid-transport, as well as the peroxisome proliferator-
activated receptor β/δ (PPAR β/δ), a ligand-activated 
transcription factor and member of the nuclear hormone 
receptors superfamily, are upregulated in psoriasis (7–9). 
The goal of this study was to assess whether mTOR, 
its upstream (PI3K and Akt) and downstream S6K1 
(specifically S6Ser235/236 and S6Ser240/244) targets, 
as well as FABP5 and PPARβ/δ, are overexpressed in 
inflamed toll-like receptor-7/8 ligand imiquimod (IMQ)-
induced Balb/c mouse skin lesions and, whether their 
expressions simulate those observed in inflamed skin 
lesions from untreated psoriatic patients compared with 
matched controls. 
MATERIALS AND METHODS
Male Balb/c mice, 6–8-week-old (Harlan laboratories, Madison, 
WI) were used in this study. Mice received a daily topical dose 
of 62.5 mg of commercially available IMQ cream (5%) (Aldara, 
3M Pharmaceuticals), on the shaved back for 5 days, and received 
the same daily booster dose for 9 additional days for a total of 
14 consecutive days to achieve optimal chronic inflammation. 
IMQ-treated (n = 6) and pair-matched control (n = 6) mouse 
skin tissues were freshly harvested as earlier described (10), for 
details of histological analyses see Appendix S11. For human 
samples, different clinical grades lesional skin from untreated 
patients with active psoriasis (n = 12), fresh healthy skin (n=10) 
taken after written and informed consent, were processed for 
histology and immunostaining (see Appendix S11). Images were 
generated using the Nuance® EX/FX and Vectra™ (PerkinEl-
mer, Boston, MA) multiplexing image technology platform and 
analyzed by the inForm software. We also analyzed changes in 
protein expression by western blotting using antibodies outlined 
in Appendix S11. 
RESULTS AND DISCUSSION
Consistent with previous reports (4, 9, 11), we observed 
upregulation of the expression and activation of PI3K/
Akt and mTOR kinases, and PPARβ/δ and FABP5 in 
human psoriatic skin lesions compared to matched con-
trol skin. Importantly, we provide evidence that these 
kinases and markers are also overexpressed in inflamed 
skin lesions of IMQ-induced mouse psoriasis-like skin 
model compared to matched controls. PI3K phosphory-
lation activates Akt which regulate multiple targets and 
cellular processes (2, 12). We observed overexpression 
of PI3K in inflamed human psoriatic and IMQ-induced 
Balb/c mouse skin lesions (Fig. S11). Full activation 
of Akt requires dual phosphorylation on Thr308 by the 
activation loop via the PI3K/ PDK1 and on Ser473 by 
mTORC2 which also promotes Thr308 phosphorylation 
by PDK1 (13). Akt hyperphosphorylation was observed 
at two sites; Ser473 (strong staining in the suprabasal/
differentiating layers with occasional punctate staining 
in the basal layers), and Thr308 (entire epidermis inclu-
ding part of the dermis) in human psoriatic (Fig. S2 
A[a, b]1 and in IMQ-induced (Fig. S2B[aa–ab]1) skin 
lesions, compared with respective controls (Fig. S2A[g, 
h] and B[ag–ah]1). The serine/threonine protein kinase 
mTOR interacts with several proteins within the rapa-
mycin-sensitive mTORC1 and the rapamycin-resistant 
mTORC2 pathways. Both complexes are differentially 
regulated and can be activated by autophosphoryla-
tion at Ser2481 and by Akt-mediated phosphorylation at 
Ser2448 (3, 14). Here, mTOR was hyperphosphorylated 
both on Ser2481 (illustrative of a predominant mTORC2 
activation) and to some extent on Ser2448 (indicative of 
mTORC1 activation) in human psoriatic (Fig. S2A[c, 
d]1) and IMQ-induced (Fig. S2B[ac–ad]1) skin lesions 
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(14). Interestingly, IMQ-treated lesions prominently 
expressed both phospho-Akt(Ser473;Thr308) and phospho-
mTOR(Ser2481; 2488) in the entire epidermis/upper dermis, 
mimicking severe psoriasis (Fig. S2B [aa–ad] and [ag–
aj]1) compared to controls (Fig. S2A[i, j]1 and B(aI–aJ)1) 
showing weak expression. 
Analyses with pan- and phospho-specific antibodies 
showed that IMQ-induced activation of Akt(Ser473) and 
downstream targets (p44/42, S6 and p90RSK, and Stat3 
in IMQ-treated skin lysates and sections (Figs S1 and 
S3A1). Activated mTORC1 transmits signal by activa-
ting ribosomal protein S6 kinase-1(S6K1), and 4E-BP1 
which regulate eukaryotic mRNA translation initiation 
and protein synthesis, whereas mTORC2 regulates 
proliferation, growth and cytoskeleton remodeling via 
Akt activation. S6 activity is a widely accepted measure 
of mTOR activity and recently reported to be activated 
in differentiating layers of inflamed psoriatic skin (15). 
Human psoriatic skin exhibited strong S6 phosphory-
lation at (Ser235/236 and Ser240/244) predominantly in the 
suprabasal/differentiating epidermal layers, whereas 
basal layers showed only a few cell with punctate 
staining (Fig. S2A[e, f]1). Consistent with human pso-
riasis, prominent overexpression of both phospho-S6 
isoforms was observed in the entire epidermis including 
part of the dermis in IMQ-treated mouse skin tissues 
(Fig. S2B[ae–af]1). However, differential phospho-S6 
expression pattern was observed among patients with 
mild, moderate/severe phenotypes. Control human and 
mouse skins revealed basaline phospho-S6 expression 
in stratum granulosum (Fig. S2A[k, l]1 and B[ak–al]1). 
By immunofluorescence with pan-lymphocytic marker 
(CD45) we observed the association of S6 phosphoryla-
tion with inflammation being more extensive in severely 
inflamed lesions than in less inflamed areas both in 
human psoriatic (Fig. S2A[f]1) and IMQ-induced (Fig. 
S2B[af]1) lesions. Intriguingly, while PI3K is over-
expressed in the basal layers, Akt/mTOR and S6 are 
hyperactivated throughout suprabasal/differentiating 
epidermal layers in lesional psoriatic skin, IMQ-induced 
lesions in mice shows hyperactivation of these makers 
in the entire epidermis, recapitulating severe psoriasis. 
FABP-5 expression was significantly increased in 
inflamed psoriatic lesions (Fig. S3B1 top panel and in-
set). We also report for the first time that IMQ-induced 
skin lesions recapitulate similar FABP5 staining (Fig. 
S3C1 and inset). We observed that PPAR β/δ, known to 
be associated with disease-promoting role in psoriasis 
(11) showed strongly increased cytoplasmic and nuclear 
activation both in inflamed human psoriatic and IMQ-
induced lesions compared with only cytoplasmic basal 
cell staining in controls (Fig. S11 and Fig. S3E1, inset). 
Interestingly, in IMQ-induced lesions prominently 
overexpressed PPARβ/δ  was particularly observed in 
suprabasal/differentiating compartments, the hair follic-
les and fibroblastic dermal cells (Fig. S3E1 and insets).
Our data reveal that topical application of IMQ is 
sufficient to activate PI3K/Akt and mTOR kinases, as 
well as the upregulation PPARβ/δ and FABP5 in the 
murine skin, in addition to recapitulating other reported 
pathological features characteristic of psoriasis. Our 
study also concurs with previous data (4, 9, 11), that 
activation of PI3K/Akt/mTOR signaling is involved in 
the pathogenesis of psoriasis. Therefore, we conclude 
that the IMQ-induced murine psoriasis-like inflamma-
tion is a useful model that can be tweaked for preclinical 
evaluation and development of pharmacologic agents 
targeting the PI3K/Akt/mTOR pathway and other di-
sease markers for the management of psoriasis. 
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